Skip to content
PubMed This is a summary of 66 peer-reviewed journal articles Updated
Metabolic Medicine

Methylmalonic Acidemia with Homocystinuria: A Patient Guide

At a Glance

Methylmalonic acidemia with homocystinuria is a rare inherited disorder in which cells cannot process vitamin B12 properly, causing methylmalonic acid and homocysteine to build up. Lifelong B12 injections, often with betaine and specialist monitoring, help control the condition and reduce complications.

Methylmalonic Acidemia with Homocystinuria (MMA-HCU) is a rare genetic condition that fundamentally changes how the body uses Vitamin B12 (cobalamin). The most common form is the cblC defect (caused by biallelic MMACHC variants), though other disorders (such as cblD, cblF, cblJ, and cblX) can produce related findings.

In most people, Vitamin B12 is easily converted into the “keys” required to unlock vital chemical reactions within the cells. For those with this condition, the cells absorb B12 but the internal machinery needed to process it is broken. This creates a double-sided problem: the body cannot perform essential tasks, and two substances—methylmalonic acid (MMA) and homocysteine (tHcy)—begin to build up to toxic levels [1][2].

The condition typically presents in one of two distinct ways depending on when symptoms first appear. The early-onset form is often diagnosed in infancy, sometimes through newborn screening, and can cause challenges with growth, muscle tone, and early neurological development [3][4]. The late-onset form can appear at any point from childhood through adulthood. In these cases, the symptoms are often more subtle and varied, potentially involving sudden changes in mood or behavior, difficulty walking, or unexplained kidney and heart issues [5][6].

Because the problem lies deep within the cells, managing the condition requires a specialized approach. Standard oral vitamins or dietary changes are not enough because the primary problem is intracellular conversion of cobalamin after uptake. Instead, the standard of care is lifelong, high-dose hydroxocobalamin injections, which provide a reliable, high exposure under specialist supervision that improves residual intracellular processing [7][8]. This treatment is often paired with other supplements, such as betaine, to help clear the buildup of homocysteine and protect the organs from damage [9].

Living with MMA-HCU requires constant vigilance because it is a multisystem condition. The elevated levels of acids can impact the eyes, potentially leading to vision loss that requires monitoring by specialized eye doctors using tools like OCT (Optical Coherence Tomography) and ERG (Electroretinography) [10]. It can also affect the kidneys (TMA or HUS) and the blood pressure in the lungs (Pulmonary Hypertension), making regular check-ups with a full team of specialists a necessity [11][5]. Furthermore, common illnesses like a fever or a stomach bug can stress the body’s metabolism, potentially triggering an emergency that requires immediate medical intervention [12].

While the diagnosis is life-changing, it is also manageable. The goal of modern treatment is to stabilize the body’s internal chemistry and prevent long-term complications. With a dedicated care team and a consistent treatment routine, individuals with MMA-HCU can focus on growth, development, and living a full life beyond their diagnosis [13].

Disclaimer: This guide provides educational information. Your emergency letter and metabolic team’s specific instructions always take priority over any general thresholds or guidance found here.

Common questions in this guide

What is methylmalonic acidemia with homocystinuria (MMA-HCU)?
MMA-HCU is a rare inherited disorder in which cells cannot properly process vitamin B12. As a result, methylmalonic acid and homocysteine build up and can affect the nervous system and several organs.
Is MMA-HCU always caused by the cblC defect?
No. cblC, caused by changes in both copies of the MMACHC gene, is the most common form, but cblD, cblF, cblJ, and cblX disorders can cause related findings.
What treatment is used for MMA-HCU?
Treatment usually includes lifelong, high-dose hydroxocobalamin injections under metabolic specialist supervision. Betaine is often added to help lower homocysteine. Oral vitamins or dietary changes alone are not enough because the main problem is how cells process B12 after it enters them.
How do early- and late-onset MMA-HCU differ?
Early-onset disease often appears in infancy, sometimes through newborn screening, and may affect growth, muscle tone, and neurological development. Late-onset disease can appear from childhood through adulthood and may cause mood or behavior changes, difficulty walking, or unexplained kidney and heart problems.
What complications should people with MMA-HCU be monitored for?
MMA-HCU can affect vision, the kidneys, the heart, and the lungs. Regular eye, kidney, heart, and lung monitoring can help identify complications such as vision loss or high blood pressure in the lungs, and an eye specialist may use OCT or ERG testing.
What should I do if I have a fever or stomach illness?
Illnesses such as fever or stomach bugs can stress metabolism and trigger an emergency. Follow the individualized sick-day plan and emergency letter from your metabolic team, and seek urgent medical help according to those instructions rather than relying on general online thresholds.
Can people with MMA-HCU live a full life?
MMA-HCU is life-changing but manageable. Consistent treatment and a dedicated care team aim to stabilize the body’s chemistry and prevent complications so people can focus on growth, development, and daily life.

Get notified when new evidence is published on Methylmalonic acidemia with homocystinuria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    The vitamin B12 processing enzyme, mmachc, is essential for zebrafish survival, growth and retinal morphology.

    Sloan JL, Achilly NP, Arnold ML, et al.

    Human molecular genetics 2020; (29(13)):2109-2123 doi:10.1093/hmg/ddaa044.

    PMID: 32186706
  2. 2

    Inherited defects of cobalamin metabolism.

    Watkins D, Rosenblatt DS

    Vitamins and hormones 2022; (119()):355-376 doi:10.1016/bs.vh.2022.01.010.

    PMID: 35337626
  3. 3

    [Kidney disease in cobalamin C deficiency].

    Lemoine M, Grangé S, Guerrot D

    Nephrologie & therapeutique 2019; (15(4)):201-214 doi:10.1016/j.nephro.2019.03.011.

    PMID: 31130431
  4. 4

    The Follow-Up of Chinese Patients in cblC Type Methylmalonic Acidemia Identified Through Expanded Newborn Screening.

    Ling S, Wu S, Shuai R, et al.

    Frontiers in genetics 2022; (13()):805599 doi:10.3389/fgene.2022.805599.

    PMID: 35242167
  5. 5

    Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review.

    Arhip L, Brox-Torrecilla N, Romero I, et al.

    Orphanet journal of rare diseases 2024; (19(1)):20 doi:10.1186/s13023-024-03021-3.

    PMID: 38245797
  6. 6

    Late-onset cblC defect: clinical, biochemical and molecular analysis.

    Ding S, Ling S, Liang L, et al.

    Orphanet journal of rare diseases 2023; (18(1)):306 doi:10.1186/s13023-023-02890-4.

    PMID: 37770946
  7. 7

    Late-onset cobalamin C disease: rare but treatable.

    Aliyar A, Endrakanti M, Singh RK, et al.

    Practical neurology 2022; doi:10.1136/practneurol-2022-003447.

    PMID: 35803728
  8. 8

    Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency?

    Scalais E, Geron C, Pierron C, et al.

    Molecular genetics and metabolism 2023; (140(3)):107681 doi:10.1016/j.ymgme.2023.107681.

    PMID: 37604084
  9. 9

    Improved biochemical and neurodevelopmental profiles with high-dose hydroxocobalamin therapy in cobalamin C defect.

    Olivieri G, Greco B, Cairoli S, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12787 doi:10.1002/jimd.12787.

    PMID: 39152755
  10. 10

    Ocular disease in the cobalamin C defect: a review of the literature and a suggested framework for clinical surveillance.

    Weisfeld-Adams JD, McCourt EA, Diaz GA, Oliver SC

    Molecular genetics and metabolism 2015; (114(4)):537-46.

    PMID: 25742969
  11. 11

    Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.

    Beck BB, van Spronsen F, Diepstra A, et al.

    Pediatric nephrology (Berlin, Germany) 2017; (32(5)):733-741 doi:10.1007/s00467-016-3399-0.

    PMID: 27289364
  12. 12

    Newborn Screening for Methylmalonic Acidemia in a Chinese Population: Molecular Genetic Confirmation and Genotype Phenotype Correlations.

    Zhou W, Li H, Wang C, et al.

    Frontiers in genetics 2018; (9()):726 doi:10.3389/fgene.2018.00726.

    PMID: 30728829
  13. 13

    Prospective evaluation of pregnancy outcome in an Italian woman with late-onset combined homocystinuria and methylmalonic aciduria.

    Grandone E, Martinelli P, Villani M, et al.

    BMC pregnancy and childbirth 2019; (19(1)):318 doi:10.1186/s12884-019-2474-5.

    PMID: 31470807

This guide about MMA-HCU is for informational purposes only and does not constitute medical advice. Follow your metabolic team’s individualized emergency and sick-day instructions, which take priority over general information here.